BSG endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis

In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.

Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, the rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis.

Read More

BSG logo
Guidance
Care Bundles
Liver
Decompensated cirrhosis: an update of the BSG/BASL admission care bundle
clinical-resource/Decompensated-Liver-Disease-CB-2025-update
This document was published in 2025.

BSG logo
Position Statements
Inflammatory Bowel Disease
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
clinical-resource/BSR-guideline-axial-spondyloarthritis-DMARDs